BioSpace News Archive

Business

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx

January 12, 2020
·
10 min read
Business

Cutera Announces Preliminary Financial Results for Fourth Quarter and Full-Year 2019

Cutera, Inc., a leading provider of energy-based aesthetic systems for practitioners worldwide, announced certain preliminary, unaudited, financial results for the fourth quarter and year ended December 31, 2019.

January 12, 2020
·
3 min read
Biotech Bay

Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer

LUNAR-1 liquid biopsy assay will be used to identify molecular residual disease and support its validation as a diagnostic biomarker

January 12, 2020
·
6 min read
Business

Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan

Mundipharma announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.

January 12, 2020
·
2 min read
Deals

Teladoc Health to Acquire InTouch Health

Acquisition creates clear leader in providing virtual care solutions for both hospitals & health systems

January 12, 2020
·
6 min read
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference

Continued investment in EBV T-cell platform to develop off-the-shelf, allogeneic CAR T immunotherapies leveraging favorable EBV T-cell safety, expansion, trafficking and persistence characteristics

January 12, 2020
·
5 min read
Biotech Bay

Agios Announces “Agios 2025” Strategic Vision and Highlights 2020 Milestones

In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline

January 12, 2020
·
8 min read
Business

Invitae preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year

Issues 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue

January 12, 2020
·
9 min read
Business

Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference

Luminex Corporation announced 2019 highlights and 2020 guidance.

January 12, 2020
·
4 min read